The deficiency of
CITRIN, the liver mitochondrial
aspartate-glutamate carrier (AGC), is the cause of four human clinical phenotypes,
neonatal intrahepatic cholestasis caused by CITRIN deficiency (
NICCD), silent period,
failure to thrive and
dyslipidemia caused by
CITRIN deficiency (FTTDCD), and
citrullinemia type II (CTLN2). Clinical symptoms can be traced back to disruption of the
malate-
aspartate shuttle due to the lack of
citrin. A potential
therapy for this condition is the expression of aralar, the AGC present in brain, to replace
citrin. To explore this possibility we have first verified that the
NADH/NAD+ ratio increases in hepatocytes from
citrin(-/-) mice, and then found that exogenous aralar expression reversed the increase in
NADH/NAD+ observed in these cells. Liver mitochondria from
citrin (-/-) mice expressing liver specific transgenic aralar had a small (~ 4-6 nmoles x mg prot-1 x min-1) but consistent increase in
malate aspartate shuttle (MAS) activity over that of
citrin(-/-) mice. These results support the functional replacement between AGCs in the liver. To explore the significance of AGC replacement in human
therapy we studied the relative levels of
citrin and aralar in mouse and human liver through absolute quantification proteomics. We report that mouse liver has relatively high aralar levels (
citrin/aralar molar ratio of 7.8), whereas human liver is virtually devoid of aralar (
CITRIN/ARALAR ratio of 397). This large difference in endogenous aralar levels partly explains the high residual MAS activity in liver of
citrin(-/-) mice and why they fail to recapitulate the human disease, but supports the benefit of increasing aralar expression to improve the redox balance capacity of human liver, as an effective
therapy for
CITRIN deficiency.